↓ Skip to main content

Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report

Overview of attention for article published in Frontiers in Pharmacology, December 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
1 news outlet
twitter
4 X users

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
3 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report
Published in
Frontiers in Pharmacology, December 2021
DOI 10.3389/fphar.2021.809467
Pubmed ID
Authors

Yadong Wang, Tiange Wang, Jianchao Xue, Ziqi Jia, Xinyu Liu, Bowen Li, Ji Li, Xiaoguang Li, Weiwei Wang, Zhongxing Bing, Lei Cao, Zhili Cao, Naixin Liang

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 3 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 3 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 1 33%
Student > Ph. D. Student 1 33%
Unknown 1 33%
Readers by discipline Count As %
Unspecified 1 33%
Nursing and Health Professions 1 33%
Unknown 1 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2022.
All research outputs
#3,664,065
of 22,828,180 outputs
Outputs from Frontiers in Pharmacology
#1,563
of 16,070 outputs
Outputs of similar age
#86,131
of 497,617 outputs
Outputs of similar age from Frontiers in Pharmacology
#95
of 1,192 outputs
Altmetric has tracked 22,828,180 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,070 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 497,617 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 1,192 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.